Total Equity
Neurocrine Biosciences Total Equity increased by 4.7% to $3.41B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 34.4%, from $2.54B to $3.41B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 23.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase generally signals growth in retained earnings or capital injections, while a decrease may indicate share buybacks, dividend payments, or net losses.
Detailed definition
This represents the residual interest in the assets of the entity after deducting all its liabilities. It reflects the n...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically maintain high equity levels to support R&D and M&A.
total_stockholders_equityHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.28B | $1.35B | $1.37B | $1.39B | $1.42B | $1.54B | $1.71B | $1.68B | $1.85B | $2.00B | $2.23B | $2.39B | $2.51B | $2.72B | $2.59B | $2.54B | $2.69B | $3.00B | $3.25B | $3.41B |
| QoQ Change | — | +5.2% | +2.1% | +1.2% | +2.3% | +8.5% | +10.6% | -1.4% | +10.0% | +8.0% | +11.5% | +6.9% | +5.2% | +8.4% | -4.8% | -2.1% | +6.3% | +11.5% | +8.3% | +4.7% |
| YoY Change | — | — | — | — | +11.3% | +14.8% | +24.3% | +21.1% | +30.2% | +29.6% | +30.7% | +41.7% | +35.4% | +35.8% | +16.0% | +6.3% | +7.4% | +10.5% | +25.6% | +34.4% |
Total Equity at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's total equity?
- Neurocrine Biosciences (NBIX) reported total equity of $3.41B in Q1 2026.
- How has Neurocrine Biosciences's total equity changed year-over-year?
- Neurocrine Biosciences's total equity increased by 34.4% year-over-year, from $2.54B to $3.41B.
- What is the long-term trend for Neurocrine Biosciences's total equity?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's total equity has grown at a 23.6% compound annual growth rate (CAGR), from $1.13B to $3.25B.
- What does total equity mean?
- The total value of the company that belongs to the shareholders after all debts are paid.